Abcam Archives

In Depth 18 Nov 2024

What is Abcam’s founder, Jonathan Milner, up to?

Since Abcam was acquired in December 2023, its founder, Jonathan Milner has been very active. Delve into his investment strategy.

November 18, 2024 - 17 minutesmins - By Jules Adam

Interview 8 Oct 2019

Biotech Hubs: A Tale of Two Cities

Life science investors differ widely across biotech hubs in Europe. At Labiotech’s recent Refresh event, two investors from Cambridge and Paris compared the progress of these hubs and discussed the challenges that need to be overcome in biotech investment. Funding is the lifeblood of early biotech startups, and investors are a crucial supplier. For this […]

October 8, 2019 - 6 minutesmins - By Jonathan Smith

Best in Biotech 2 Apr 2019

The 8 Best Biotech Companies in Europe’s History

We’ve put together a list of the best biotech companies in Europe to celebrate their invaluable contributions to science and the development of the booming industry that biotech is today. Though the beginnings of the biotech industry are commonly traced back to the US, Europe has stepped up as a major contender and ally in […]

April 2, 2019 - 8 minutesmins - By Clara Rodríguez Fernández

News and Trends 22 Jan 2018

Abcam Will Start Selling Over 700 Antibodies from Roche

Abcam and Roche have entered an agreement that will let Abcam sell 760 new antibodies to researchers worldwide through its online platform. Inspired by Amazon, Abcam has become one of Europe’s biggest biotechs by building a platform to make it easier for researchers to order the antibodies they need for their experiments. A new deal with […]

January 22, 2018 - 2 minutesmins - By Clara Rodríguez Fernández

abcam axiomx acquisition milestone antibody

More News! 18 May 2017

Abcam Makes Final Payment in the Acquisition of an US Antibody Biotech

Abcam has paid US-based AxioMx a final €4.5M milestone based on performance, completing an acquisition that totals €36.4M. Giant antibody maker Abcam, founded by star biotech entrepreneur Jonathan Milner and based in Cambridge, has announced it made the last payment part of its acquisition deal with AxioMx. The deal was initiated in November 2015 with a […]

May 18, 2017 - 1 minutemin - By Clara Rodríguez Fernández

Interview 27 Mar 2017

Meet one of the Most Successful Biotech Entrepreneurs in the UK

Jonathan Milner is a rockstar biotech entrepreneur and founder of Abcam. He is still on the board of his baby Abcam, while investing in many young startups, nurturing the British biotech ecosystem and taking part in philanthropy. Here’s my chat with him on all these topics. “I was amazed by how you could order books […]

March 27, 2017 - 7 minutesmins - By Philip Hemme

News and Trends 8 Oct 2015

Rabbit Antibodies proven to be more specific than Mice in Immuno-oncology PD-L1 Research

Abcam is a Cambridge (UK) Biotech who have developed a monoclonal antibody (mAB) production platform from rabbits. This platform is developed for a much more specific immunohistochemical alternative to the traditional Rodent equivalents. Now the most recent generation of mAbs from this platoform is able to detect PD-L1 tumor proteins for immuno-oncology research. The conventional […]

October 8, 2015 - 3 minutesmins - By Dani Bancroft

News and Trends 13 Sep 2015

What happened this week? An award for Kymab, disappointment for Crowdfunding and some Wasps to save us!

Monday: A report said that the total value of crowdfunded Biotech projects from within the EU since 2010 is €23M. Tuesday: Researchers from University of Leeds unraveled the mechanism of cancer-targeting effects of Wasp venom. Wednesday: Kymab has been listed in the Sunday Times Tech Track ‘One’s to Watch’ 2015 just this month! Thursday: CureVac just announced the opening of its subsidiary […]

September 13, 2015 - 1 minutemin - By Joachim Eeckhout

News and Trends 11 Sep 2015

Cambridge Love Triangle: Leading Biotechs Abcam and Horizon finally collaborate together

This is the story of how Abcam and Horizon fell in collaborative-biotech-love and finally came together to partner up on antibody research. Whilst doing his post-doc at University of Cambridge, Jonathan Milner had an idea to improve how antibodies could be produced for researchers around the World. Thus, he founded the company Abcam in 1998. Over […]

September 11, 2015 - 2 minutesmins - By Philip Hemme

Knowledge hub

Categories

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Abcam

What is Abcam’s founder, Jonathan Milner, up to?

Biotech Hubs: A Tale of Two Cities

The 8 Best Biotech Companies in Europe’s History

Abcam Will Start Selling Over 700 Antibodies from Roche

Abcam Makes Final Payment in the Acquisition of an US Antibody Biotech

Meet one of the Most Successful Biotech Entrepreneurs in the UK

Rabbit Antibodies proven to be more specific than Mice in Immuno-oncology PD-L1 Research

What happened this week? An award for Kymab, disappointment for Crowdfunding and some Wasps to save us!

Cambridge Love Triangle: Leading Biotechs Abcam and Horizon finally collaborate together

Subscribe to our newsletter to get the latest biotech news!

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

The top biotech deals of March 2025

The biggest biotech funding rounds in March 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

Beyond amyloid: The search for the next big thing in Alzheimer’s treatment

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!